Genmab A/S
21.62
-0.10 (-0.46%)
At close: Jan 14, 2025, 3:59 PM
20.89
-3.38%
Pre-market Jan 15, 2025, 06:10 AM EST
undefined%
Bid 20.67
Market Cap 13.73B
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) 0.98
PE Ratio (ttm) 22.06
Forward PE n/a
Analyst Buy
Ask 20.71
Volume 794,560
Avg. Volume (20D) 1,242,703
Open 22.00
Previous Close 21.72
Day's Range 21.59 - 22.08
52-Week Range 19.85 - 31.88
Beta undefined

About GMAB

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esoph...

Industry Biotechnology
Sector Healthcare
IPO Date Jun 1, 2009
Employees 2,635
Stock Exchange NASDAQ
Ticker Symbol GMAB

Analyst Forecast

According to 7 analyst ratings, the average rating for GMAB stock is "Buy." The 12-month stock price forecast is $49, which is an increase of 126.64% from the latest price.

Buy 71.43%
Hold 28.57%
Sell 0.00%
Stock Forecasts

Next Earnings Release

Genmab A/S is scheduled to release its earnings on Feb 12, 2025, during market hours.
Analysts project revenue of $886.73M, reflecting a 31.36% YoY growth and earnings per share of 0.39, making a 8.33% increase YoY.
4 months ago · Source
-2.02%
Genmab shares are trading lower after JP Morgan do... Unlock content with Pro Subscription
9 months ago · Source
+1.19%
Genmab shares are trading higher. The company announced it will acquire ProfoundBio for $1.8 billion in cash.